Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T02:20:04.167Z Has data issue: false hasContentIssue false

Selecting an Antiretroviral Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis in the Occupational Setting

Published online by Cambridge University Press:  10 May 2016

Darrell H. S. Tan*
Affiliation:
Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada Division of Infectious Diseases, University of Toronto, Toronto, Ontario, Canada
Blessing Goddey-Erikefe
Affiliation:
Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada
Deborah Yoong
Affiliation:
Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada
Mark Naccarato
Affiliation:
Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada
Susan Mclntyre
Affiliation:
Corporate Health and Safety, St. Michael's Hospital, Toronto, Ontario, Canada
Roohi Qureshi
Affiliation:
Corporate Health and Safety, St. Michael's Hospital, Toronto, Ontario, Canada
Kevin Gough
Affiliation:
Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada Division of Infectious Diseases, University of Toronto, Toronto, Ontario, Canada
*
30 Bond Street, 4CC, Room 4-179, Toronto, Ontario M5B 2W9, Canada (darrell.tan@gmail.com)
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2014

References

1. Kuhar, DT, Henderson, DK, Struble, KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol 2013;34:875892.Google Scholar
2. Mayer, KH, Mimiaga, MJ, Gelman, M, Grasso, C. Raltegravir, te-nofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012;59:354359.Google Scholar
3. McAllister, J, Read, P, McNulty, A, Tong, W, Ingersoll, A, Carr, A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med 2014;15:1322.Google Scholar
4. Tosini, W, Muller, P, Prazuck, T, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS 2010;24:23752380.Google Scholar
5. Wheeler, WH, Ziebell, RA, Zabina, H, et al. Prevalence of trans mitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.—2006. AIDS 2010;24:12031212.Google Scholar
6. Eron, JJ, Young, B, Cooper, DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396407.Google Scholar
7. Barnes, S, Loutfy, M, Prasad, R, Tan, DHS. Institutional policies and physician prescribing practices of non-occupational postexposure prophylaxis (nPEP) in Ontario. In: 21st Canadian Conference on HIV/AIDS Research; 2012; Montreal, Canada. Abstract P158.Google Scholar
8. Kunches, LM, Meehan, TM, Boutwell, RC, McGuire, JF. Survey of nonoccupational HIV postexposure prophylaxis in hospital emergency departments. J Acquit Immune Defic Syndr 2001;26:263265.CrossRefGoogle ScholarPubMed